目的 探讨阿立哌唑与帕利哌酮治疗酒精所致精神障碍的临床疗效及安全性.方法 将86例酒精所致精神障碍患者采用掷币法随机分为两组,分别口服阿立哌唑、帕利哌酮治疗,观察6周.于治疗前后采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应.结果 治疗第6周末,阿立哌唑组显效率为88.6%,总有效率为97.7%;帕利哌酮组显效率为88.1%,总有效率为95.2%,两组比较差异无显著性(P>0.05).治疗第2周起两组阳性与阴性症状量表总分均较治疗前显著降低(P<0.01),同期两组间比较差异无显著性(P>0.05).阿立哌唑组不良反应发生率为31.8%,帕利哌酮组为28.5%,两组比较差异无显著性(P>0.05).结论 阿立哌唑与帕利哌酮治疗酒精所致精神障碍疗效显著且相当,安全性高,患者依从性较好.%Objective To explore the efficacy and safety of aripiprazole vs. paliperidone in the treatment of mental disorders due to alcohol (MDA). Methods According to toss 86 MDA patients were assigned to two groups taking orally aripiprazole or paliperidone for 6 weeks. Efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS). Results At the end of the 6th week effective and total effective rate were respectively 88.6% and 97.7% in aripiprazole and 88.1% and 95.2% in paliperidone group,which showed no significant differences (P>0.05). Since the 2nd week the total PANSS scores of both groups lowered more significantly compare with pretreatment (P<0.01) and group difference wasn't significant in the corresponding period. The incidence of adverse reactions was respectively 31.8% in aripiprazole and 28.5% in paliperidone group and group difference wasn't significant (P>0.05). Conclusion Both aripiprazole and paliperidone have an evident effect,higher safety and better compliance in MDA.
展开▼
